Patent application number | Description | Published |
20090082274 | Collections of repeat proteins comprising repeat modules - The present invention relates to collections of repeat proteins comprising repeat modules which are derived from one or more repeat units of a family of naturally occurring repeat proteins, to collections of nucleic acid molecules encoding said repeat proteins, to methods for the construction and application of such collections and to individual members of such collections. | 03-26-2009 |
20110207668 | BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 08-25-2011 |
20110224100 | DESIGNED ARMADILLO REPEAT PROTEINS - The invention relates to collections of target-specific designed binding proteins based on armadillo repeat proteins, and to a method of generating them. Designed armadillo repeat proteins are based on consensus sequences of single armadillo repeat units. These repeat proteins can be used as scaffolds for peptide recognition. Such a scaffold provides a binding mode that is in principle the same for every small recognizable unit, e.g. an amino acid or dipeptide, allowing a precise and modular recognition of a peptide in extended conformation. The method allows to generate a series of modules recognizing these simple units, and to combine such building blocks to create a binding site for any desired peptide target without performing additional selections. | 09-15-2011 |
20120142611 | REPEAT PROTEIN FROM COLLECTION OF REPEAT PROTEINS COMPRISING REPEAT MODULES - A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules. | 06-07-2012 |
20130116197 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 05-09-2013 |
20140221295 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 08-07-2014 |
Patent application number | Description | Published |
20080255639 | METHOD AND DEVICE FOR TREATING TISSUE USING A COAGULATED BEAM PATH - The invention disclosed herein is directed to methods and devices for treating tissue having an overlying portion and an underlying portion by using a first fractional optical energy treatment to coagulate a plurality of zones in the overlying portion, thereby reducing the optical scattering of the overlying portion, and directing a subsequent fractional optical energy treatment through the coagulated zones to the underlying portion in order to produce an effective treatment in the underlying portion of a region of tissue. The methods and devices disclosed can further comprise detection and treatment of subsurface targets in the underlying portion of tissue. The treatment parameters used to deliver the first and subsequent treatments, including wavelength, can be optimized in order to provide a first optical treatment that effectively coagulates the overlying portion and a subsequent one or more optical treatments that effectively treat the underlying portion. | 10-16-2008 |
20130178916 | SYSTEM, DEVICES, AND METHODS FOR OPTICALLY CLEARING TISSUE - Embodiments of the present disclosure provides systems, devices, and methods for non-invasively modifying, maintaining, or controlling local tissue optical properties. Methods and devices of the disclosure may be used for optically clearing tissue, for example, for diagnostic and/or therapeutic purposes. A method of optically clearing a tissue may comprise contacting the tissue with an optical clearing device having a base, an array of pins fixed to one side of the base, a brim fixed to the base, an inlet port in the base, an exit port in the base, and a handpiece interface tab fixed to the side of the base opposite the array of pins, applying a mechanical force to the tissue, and illuminating said tissue with at least one wavelength of light through the optical clearing device. A method may further comprise controlling the temperature of the tissue illuminated. | 07-11-2013 |